Plain-English translation of NCT06981078 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether (UPB-101), a new medication given by injection under the skin, can help people with moderate-to-severe COPD improve their breathing and overall lung health. About 666 adults will be randomly assigned to receive one of two doses of the medication or a placebo (a dummy injection with no medicine) every 12 or 24 weeks, while continuing their regular COPD medications. Researchers will track how well the medication works and whether it is safe over nearly two years of treatment and follow-up.
Current COPD treatments help many people, but some patients still struggle with ongoing symptoms and flare-ups despite taking their medications regularly. This trial is investigating whether this new treatment approach might offer additional benefit by working through a different mechanism to reduce lung inflammation and help patients breathe easier.
If you qualify, you would start with a 4-week screening period to confirm your eligibility. Then you would be randomly assigned to receive either the medication at one of two different doses or placebo, given as injections under your skin every 12 or 24 weeks. Your treatment would continue for about 96 weeks (roughly 2 years), followed by a 16-week follow-up period after your last injection. During this time, you would have regular clinic visits to check your lung function, monitor for any side effects, and report how you are feeling.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
United States